Related Experiment Video

Updated: Dec 2, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients

Lluís Masana1, Eudald Correig2, Cèlia Rodríguez-Borjabad1

  • 1CIBERDEM, Universitat Rovira i Virgili, LIPIDCAS, University Hospital Sant Joan IISPV, Reus, Spain.

European Heart Journal. Cardiovascular Pharmacotherapy
|November 2, 2020
PubMed

Insights

Statin therapy (ST) at hospital admission for COVID-19 was associated with reduced in-hospital mortality. These findings suggest that statin therapy should not be discontinued during the pandemic or for patients hospitalized with COVID-19.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Epidemiology

Background:

  • COVID-19 poses a significant mortality risk, particularly in older patients with comorbidities.
  • Statin therapy is widely used for cardiovascular disease prevention and management.
  • The impact of pre-existing statin therapy on COVID-19 outcomes requires further investigation.

Purpose of the Study:

  • To assess the effect of statin therapy (ST) initiated before or during hospitalization on in-hospital mortality among COVID-19 patients.
  • To analyze the association between statin use and COVID-19 related mortality risk.

Main Methods:

  • Retrospective observational study of 2157 SARS-CoV-2 infected patients.
  • Genetic matching (GM) procedure to control for confounding factors like age and comorbidities.
  • Analysis using Cox proportional hazards model for cause-specific hazard (CSH) and competing-risks Fine and Gray (FG) model.

Main Results:

  • Patients on statins were older and had more comorbidities than non-statin users.
  • Univariate analysis after GM showed significantly lower mortality in patients on ST (19.8%) versus the matched non-statin group (25.4%).
  • Patients maintaining statin treatment during hospitalization had even lower mortality (17.4%).
  • Both Cox (HR=0.58) and FG (HR=0.60) models indicated statins are associated with reduced COVID-19 mortality.

Conclusions:

  • Statin therapy prior to hospitalization is associated with lower SARS-CoV-2 infection-related mortality.
  • Discontinuation of statin therapy is not recommended for patients hospitalized with COVID-19.
  • Maintaining statin therapy may be beneficial for improving outcomes in COVID-19 patients.
Abstract

Keywords:
COVID-19Cardiovascular riskMortalitySARS-CoV-2Statins

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.9K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
212
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
145
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
497
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
91
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
123